{
    "name": "histrelin",
    "comment": "Rx",
    "other_names": [
        "Supprelin LA",
        "Vantas"
    ],
    "classes": [
        "Antineoplastics",
        "GNRH Agonists"
    ],
    "source": "https://reference.medscape.com/drug/supprelin-la-vantas-histrelin-342758",
    "pregnancy": {
        "common": [
            "Contraindicated during pregnancy since expected hormonal changes that occur with treatment increase risk for pregnancy loss; the limited data with histrelin use in pregnant women are insufficient to determine a drug-associated risk for major birth defects or adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Reproductive potential",
                "description": [
                    "Based on findings in animals and mechanism of action, therapy may impair fertility in males of reproductive potential"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Consistent with mechanism of action, animal reproduction studies showed an increase in fetal loss at clinically relevant exposures"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of drug in human or animal milk, effects on breastfed infant, or on milk production; absorption and systemic activity are not expected from potential exposure to drug, in breast milk; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Women who may become or are currently pregnant, children"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists",
                "Cases of spinal cord compression, which may contribute to weakness or paralysis with or without fatal complications, have been reported with GnRH agonists",
                "Convulsions reported in patients receiving GnRH agonists; reports with GnRH agonists have included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs; convulsions also reported in patients in the absence of any of the conditions listed",
                "Psychiatric events reported in patients taking GnRH agonists; postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression; monitor for development or worsening of psychiatric symptoms during treatment",
                "Reports of MI, sudden cardiac death, and stroke in men treated with GnRH agonists",
                "Pseudotumor cerebri (idiopathic intracranial hypertension) reported in pediatric patients receiving GnRH agonists, including leuprolide acetate; monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea"
            ],
            "specific": [
                {
                    "type": "QT prolongation",
                    "description": [
                        "Androgen deprivation therapy may prolong the QT/QTc interval; consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval",
                        "Electrolyte abnormalities should be corrected",
                        "Consider periodic monitoring of ECG and electrolytes"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fluid retention",
            "percent": null
        },
        {
            "name": "peripheral edema",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "ventricular extrasystoles",
            "percent": null
        },
        {
            "name": "Various pain",
            "percent": null
        },
        {
            "name": "Renal calculi",
            "percent": null
        }
    ]
}